Cross-reacting material in congenital factor VIII deficiencies (Haemophilia A and von Willebrand's disease)
Thrombosis ResearchPublished 1 April 1972
Dominique Meyer, Jean‐Maurice Lavergne, M J Larrieu, F Josso
Citations86
SJR quartileQ2
SJR score0.97
SNIP1.03
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Using a heterologous specific and precipitating anti human Factor VIII antiserum, the presence of cross-reacting material (C.R.M.) was detected in cryoprecipitate as well as in plasma of 83 patients with Haemophilia A and 15 patients with von Willebrand's disease.
Abstract
Using a heterologous specific and precipitating anti human Factor VIII antiserum, the presence of cross-reacting material (C.R.M.) was detected in cryoprecipitate as well as in plasma of 83 patients with Haemophilia A (49 without and 34 with a circulating Factor VIII antibody). The ratio of Factor VIII activity to antigen was lower in known carriers of Haemophilia than in normal women. In 15 patients with von Willebrand's disease, C.R.M. was absent or seemed only to be proportional to the amount of biologically active Factor VIII.
Keywords
Medicine
Analytical BiochemistryQuantitative estimation of proteins by electrophoresis in agarose gel containing antibodies
4,431 Citations1966Carl‐Bertil Laurell
The method utilizes the difference between the rate of electrophoretic migration of proteins and of their antibody complexes in agarose gel to perform quantitative analysis of proteins with a charge differing from that of the bulk of the immunoglobulins.
Journal of Clinical InvestigationImmunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease
660 Citations1971T S Zimmerman, Oscar D. Ratnoff +1 more
The experiments described suggest that von Willebrand's disease is a disorder in which a true deficiency of AHF exists andMaterial antigenically similar to normal AHF was detected in normal amounts in plasma concentrates in each of 22 patients with classic hemophilia, in a patient with an acquired circulating anticoagulant against AHF, and in a patients with deficiencies both of AHf and proaccelerin.
Journal of Clinical InvestigationDetection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (factor VIII)
186 Citations1971T S Zimmerman, Oscar D. Ratnoff +1 more
The relation between functional antihemophilic factor activity and AHF-like antigen was studied in the plasma of 25 known carriers of hemophilia, and the data are consistent with the hypothesis that the proportion of antigen to AHF activity in carriers is determined by random activation or inactivation of the X chromosome.
British Journal of HaematologyMethods for the Production of Clinically Effective Intermediate and High‐Purity Factor‐VIII Concentrates
176 Citations1971Jack Newman, Alan J. Johnson +2 more
An intermediate and a high‐purity factor‐VIII concentrate for clinical use have been prepared on a large scale by cryoethanol precipitation, extraction of the precipitate with tris buffer, and fractionation with polyethylene glycol.
Nature New BiologyImmunological Characterization of Purified Anti-Haemophilic Factor A (Factor VIII) which corrects Abnormal Platelet Retention in Von Willebrand's Disease
165 Citations1972Barend Bouma, Y. WLEGERINCK +3 more
Normal platelet retention in a column of glass beads, which has been described in cases of Von Willebrand's disease, is corrected in vitro by cryoprecipitate prepared from normal plasma and partially purified factor VIII concentrates although fibrinogen is ineffective.
BloodImmunologic Studies of Antihemophilic Factor (AHF, Factor VIII): Cross-Reacting Material in a Genetic Variant of Hemophilia A
142 Citations1968Leon W. Hoyer, Robert T. Breckenridge
Plasmas from two of twenty-seven families with hemophilia A have a cross-reacting material which inactivates an anticoagulant to AHF.
The LancetIMMUNOLOGICAL DIFFERENTIATION OF THREE TYPES OF HÆMOPHILIA AND IDENTIFICATION OF SOME FEMALE CARRIERS
85 Citations1970Enid Bennett, E. R. Huehns
Heterozygotes in families in which the haemophilic members show normal levels of protein have been recognised by finding excess of factor-VIII-like protein in the plasma, as compared with the biological activity present.
ScienceHemophilia A: Polymorphism Detectable by a Factor VIII Antibody
72 Citations1969Donald I. Feinstein, May N. Y. Chong +2 more
Most patients with hemophilia A do not synthesize factor VIII, whereas a few synthesize an inactive molecule with a presumed genetic structural mutation of the active site but with antigenic determinants in common with normal factor VIII.